Accentia settles investor suit for $1.35M; NIH awards Emergent, PharmAthene next-gen anthrax vax contracts;

> Accentia ($ABPI) has struck a $1.25 million deal to end an investor suit claiming that it lied to investors about the performance of an in-development non-Hodgkin's lymphoma treatment vaccine. Report (reg. req.)

> Emergent BioSolutions ($EBS) and PharmAthene ($PIP) have won contracts worth $28 million-plus each from the NIH to make next-generation anthrax vaccines. More | Release

> BiondVax has received a grant of 4.87 million NIS ($1.3 million) from Israel's Ministry of Economy to continue the clinical program for its universal influenza vaccine. More

> The U.S. has issued a patent for Soligenix's ($SGNX) ThermoVax technology. Release

And Finally... Researcher Jean-Marie Andrieu believes he has found a drinkable, probiotic-rich vaccine to ward off HIV. More

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

As a new coronavirus spreads, vaccine researchers have started work on candidates against the virus—and one could enter the clinic in a few months.

Merck's HPV vaccine Gardasil is delivering blockbuster sales as demand surges. But high demand has caused somewhat of a supply constraint.